Lifestyle Drugs Market Report

Lifestyle Drugs Market Analysis, Market Size, Application Analysis, Regional Outlook, Competitive Strategies and Forecasts, 2015 To 2022

Format: PDF  |  Report ID: GVR1866

Lifestyle drugs market is luring various pharmaceutical companies globally and is anticipated to grow substantially over the forecast period. Key driver for the lifestyle drugs market is increasing usability of these drugs by all age groups, rising demand to enhance life expectancy and reduce the ageing process. Increasing demand of individuals to be physically fit along with normal and enhanced functioning of all body parts is the vital driver of the growth of the market. Few advantages offered, that spur the growth of the market include the ability of these drugs to cater to modern man’s lifestyle needs such as vigor, youth, beauty, intelligence, and personality. Reduction in disease occurrence, improved stamina, improvement in memory and concentration, curbing impulses and others also contribute to the growth of market. Other drivers of the market are increasing awareness level of individuals, enhancing access to healthcare facilities, growing spending by individuals, changing demographics across the globe and aggressive marketing and branding strategies by the market players. Majority of the drugs belonging to lifestyle market are OTC (over the counter) products, thus eliminating the need to visit a clinic or hospital, which adds to the growth of the market. Lifestyle drugs market growth is also co-dependent on the cosmetic market due to rising aesthetic appeal is further expected to fuel the growth of the market.

The lifestyle drugs market is segmented on the basis of product. The various types of product available are classified into seven categories namely; anti-depressant, hair loss reduction agents, smoking withdrawal, fat burner/ anti cholesterol drugs, contraceptives, potency, and anti-wrinkle agents. Potency and contraceptive drugs held the largest market share owing to their growing popularity and utilization. Viagra from Pfizer is the largest selling product followed by Eli Lily’s Cialis. These two drugs together have reported a sale of over USD 4 million in 2010, thus being the largest contributors to the segment. Fat burners or anti-obesity drugs are expected to witness the fastest growth during the forecast period due to change in eating habits and increasing population of obese people. Anti-wrinkle agents are also expected to witness lucrative growth during the forecast period. Addition of new segments such as dental products into the product portfolio is expected to occur during the forecast period, further fueling the growth.

North America is expected to dominate lifestyle drugs market over the forecast period due to higher disposal income, rising urban population base which are conscious and aware of their health and appearance, and increasing new drug development. Along with the above contributors, stringent FDA norms to obtain approval and sale of these drugs highlight the high quality and safety of the drugs propelling further growth of the market. European market is expected to retain its position with stable growth over the forecast period. Stable growth is attributed to lesser investment in development of new lifestyle drugs and instead earning profits by existing products. Asia Pacific is expected to witness the fastest growth during the forecast period majorly due to the enhancing availability of such drugs in the region and growth in number of generic market players. Various companies are expected to conduct intensive R&D and launch an array of drugs adding to the portfolio of lifestyle products market. Aggressive marketing and establishment of emotional appeal has led to the substantial growth of the market in the region.

Key companies and players of the market are Pfizer, Eli Lily, Teva Pharmaceuticals, Biocon Ltd., Mylan pharmaceuticals, GlaxoSmithKline, McNeil, Johnson & Johnson, Merck & Co. Inc., Dr. Reddy’s Laboratories, Zydus Cadila, Cipla, Sun Pharmaceuticals, Nicholas Piramal, Alembic, Proctor & Gamble, Astrazeneca, Novo Nordisk, Amgen, Lupin and various others. Viagra from Pfizer has by far been the largest profit making drug of the market due to the marketing innovations of the company, until generic companies combated reducing the profit shares. Introduction of various new entrants and SME’s are expected to heighten the competition of the market.

 

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $4,950
Multi User - $5,950
Library Access - $7,950

Buy Chapters or Sections

Avail customized purchase options to meet your research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Custom research service

    Custom research service

    Speak to the report author to design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service excellence represented in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • BOA